Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 6777276, dated October 14, 1980, and corrected at 45 FR 69296, October 20 1980, as amended most recently at 17 FR 50065, dated August 24, 2006) is amended to reflect the title change for the Division of Hereditary Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Coordinating Center for Health Promotion, Centers for Disease Control and Prevention.

Section CB, Organization and Functions, is hereby amended as follows:

Delete in its entirety the title for the Division of Hereditary Blood Disorders (CUBD), and insert the Division of Blood Disorders (CUBD).

Dated: November 15, 2006.
William H. Gimson,
Chief Operating Officer, Centers for Disease Control and Prevention (CDC).
[FR Doc. 069472 Filed 112906; 8:45 am]
BILLING CODE 416018M ]]> http://thefederalregister.com/d.p/2006-11-30-06-9472 Thu, Nov 30 2006 11:00:00 GMT http://thefederalregister.com/d.p/2006-11-30-E6-20265

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 14, 2006, from 8 a.m. to 6 p.m.

Location: Crown Plaza Silver Spring, 8777 Georgia Ave, Silver Spring, MD. The hotel telephone number is 3015890800.

Contact Person: Donald W. Jehn, or Pearline K. Muckelvene, Center for Biologics Evaluation and Research (HFM71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 3018270314, or FDA Advisory Committee Information Line, 18007418138 (301443 0572 in the Washington, DC area), code 3014519516. Please call the Information Line for uptodate information on this meeting.

Agenda: On December 14, 2006, the committee will hear an update summary ]]> http://thefederalregister.com/d.p/2006-11-30-E6-20265 Thu, Nov 30 2006 11:00:00 GMT http://thefederalregister.com/d.p/2006-11-30-E6-20264

The table gives figures for each of the 50 States, the District of Columbia, Puerto Rico, the Virgin Islands, Guam, American Samoa, and the C ]]> http://thefederalregister.com/d.p/2006-11-30-E6-20264 Thu, Nov 30 2006 11:00:00 GMT http://thefederalregister.com/d.p/2006-11-30-06-9469

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
[[Page 69212]]
as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Development and Discovery.

Date: February 79, 2007.

Time: 5 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Peter J. Wirth, PhD, Scientific Review Administrator, Research ]]> http://thefederalregister.com/d.p/2006-11-30-06-9469 Thu, Nov 30 2006 11:00:00 GMT http://thefederalregister.com/d.p/2006-11-30-06-9468

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. [[Page 69213]]

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Health Behavior in SchoolAged Children (HBSC) StudyUS.

Date: December 1, 2006.

Time: 12 p.m. to 1 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852 (T ]]> http://thefederalregister.com/d.p/2006-11-30-06-9468 Thu, Nov 30 2006 11:00:00 GMT http://thefederalregister.com/d.p/2006-11-30-06-9467

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Emphasis Panel; Minority Biomedical Research Support SCORE and RISE.

Date: December 1, 2006.

Time: 9:30 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Room 3AN12, Bethesda, MD 20892 (Telephone Conference Ca ]]> http://thefederalregister.com/d.p/2006-11-30-06-9467 Thu, Nov 30 2006 11:00:00 GMT http://thefederalregister.com/d.p/2006-11-30-06-9466

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; GENSAT Review.

Date: November 29, 2006.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: ]]> http://thefederalregister.com/d.p/2006-11-30-06-9466 Thu, Nov 30 2006 11:00:00 GMT http://thefederalregister.com/d.p/2006-11-30-06-9470

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy

Name of Committee: National Institute on Aging Special Emphasis Panel; Gene Delivery for Alzhiemer Disease.

Date: December 1, 2006.

Time: 11 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, 2C212, Bethesda, MD 20814. (Telephone Conference Call).

Contact Person: Rames ]]> http://thefederalregister.com/d.p/2006-11-30-06-9470 Thu, Nov 30 2006 11:00:00 GMT